Smac mimetics and innate immune stimuli synergize to promote tumor death

Nature Biotechnology

Volumn 32, Issue 2, 2014, Pages 182-190

  Beug, Shawn T ^a   Tang, Vera A ^a   LaCasse, Eric C ^a   Cheung, Herman H ^a   Beauregard, Caroline E ^a   Brun, Jan ^a   Nuyens, Jeffrey P ^a   Earl, Nathalie ^a   St Jean, Martine ^a   Holbrook, Janelle ^a   Dastidar, Himika ^b   Mahoney, Douglas J ^b   Ilkow, Carolina ^c   Le Boeuf, Fabrice ^c   Bell, John C ^c,d   Korneluk, Robert G ^c,d  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; CYTOKINES; DRUG SYNERGISM; FEMALE; HEK293 CELLS; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; ONCOLYTIC VIROTHERAPY; POLY I-C;

EID: 84893825107     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2806     Document Type: Article

References (47)

1. Fulda, S. & Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124 (2012
2. LaCasse, E.C. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett. 332, 215-224 (2013
3. Dougan, M. et al. IAP inhibitors enhance co-stimulation to promote tumour immunity. J. Exp. Med. 207, 2195-2206 (2010
4. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012
5. Gyrd-Hansen, M. & Meier, P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10, 561-574 (2010
6. Vandenabeele, P. & Bertrand, M.J. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat. Rev. Immunol. 12, 833-844 (2012
7. Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci. Signal. 5, ra22 (2012
8. Beug, S.T., Cheung, H.H., LaCasse, E.C. & Korneluk, R.G. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol. 33, 535-545 (2012
9. Mahoney, D.J. et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. USA 105, 11778-11783 (2008
10. Li, L. et al. A small molecule Smac mimic potentiates TRAIL-And TNF{alpha}-mediated cell death. Science 305, 1471-1474 (2004
11. Varfolomeev, E. et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131, 669-681 (2007
12. Vince, J.E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693 (2007
13. Petersen, S.L. et al. Autocrine TNFalpha signalling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445-456 (2007
14. Gaither, A. et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumour necrosis factor-Alpha signalling. Cancer Res. 67, 11493-11498 (2007
15. Cheung, H.H., Mahoney, D.J., Lacasse, E.C. & Korneluk, R.G. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res. 69, 7729-7738 (2009
16. Cheung, H.H. et al. Smac mimetic compounds potentiate interleukin-1 beta-mediated cell death. J. Biol. Chem. 285, 40612-40623 (2010
17. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010
18. Chen, G., Shaw, M.H., Kim, Y.G. & Nunez, G. NOD-like receptors: Role in innate immunity and inflammatory disease. Annu. Rev. Pathol. 4, 365-398 (2009
19. McFadden, G., Mohamed, M.R., Rahman, M.M. & Bartee, E. Cytokine determinants of viral tropism. Nat. Rev. Immunol. 9, 645-655 (2009
20. Russell, S.J., Peng, K.W. & Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012
21. Houghton, P.J. et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 636-639 (2012
22. Chen, K.F. et al. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem. Pharmacol. 84, 268-277 (2012
23. Dhuria, S. et al. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, in vitro and in vivo in healthy subjects. J. Clin. Pharmacol. 53, 642-653 (2013
24. Breitbach, C.J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumour blood flow. Mol. Ther. 15, 1686-1693 (2007
25. Vaha-Koskela, M.J. et al. Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J. Virol. 87, 2363-2366 (2013
26. Le Boeuf, F. et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat. Commun. 4, 1974 (2013
27. Kawai, T. & Akira, S. Innate immune recognition of viral infection. Nat. Immunol. 7, 131-137 (2006
28. Kirshner, J.R., Karpova, A.Y., Kops, M. & Howley, P.M. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J. Virol. 79, 9320-9324 (2005
29. Bose, S., Kar, N., Maitra, R., DiDonato, J.A. & Banerjee, A.K. Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses. Proc. Natl. Acad. Sci. USA 100, 10890-10895 (2003
30. Rosenfeld, M.R. et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro-oncol. 12, 1071-1077 (2010
31. Butowski, N. et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: A North American Brain Tumour Consortium (NABTC01-05). J. Neurooncol. 91, 175-182 (2009
32. Butowski, N. et al. A North American brain tumour consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J. Neurooncol. 91, 183-189 (2009
33. Krieg, A.M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22, 77-89 (2012
34. Erickson, R.I. et al. Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-Alpha pharmacology. Toxicol. Sci. 131, 247-258 (2013
35. Wong, H. et al. Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: A translational toxicokinetic/ toxicodynamic analysis. Toxicol. Sci. 130, 205-213 (2012
36. Cantaert, T., Baeten, D., Tak, P.P. & van Baarsen, L.G. Type I IFN and TNFalpha cross-regulation in immune-mediated inflammatory disease: Basic concepts and clinical relevance. Arthritis Res. Ther. 12, 219 (2010
37. Yarilina, A. & Ivashkiv, L.B. Type I interferon: A new player in TNF signalling. Curr. Dir. Autoimmun. 11, 94-104 (2010
38. Lu, J. et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol. Cancer Ther. 10, 902-914 (2011
39. Sun, H. et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 129, 15279-15294 (2007
40. Bertrand, M.J. et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700 (2008
41. Enwere, E.K. et al. TWEAK and cIAP1 regulate myoblast fusion through the noncanonical NF-kappaB signalling pathway. Sci. Signal. 5, ra75 (2012
42. Stojdl, D.F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275 (2003
43. Brun, J. et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18, 1440-1449 (2010
44. Le Boeuf, F. et al. Synergistic interaction between oncolytic viruses augments tumour killing. Mol. Ther. 18, 888-895 (2010
45. Lun, X. et al. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol. Ther. 18, 1927-1936 (2010
46. Mikus, J. & Steverding, D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol. Int. 48, 265-269 (2000
47. Chou, T.C. & Talaly, P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252, 6438-6442 (1977